GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Trial Profile

GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Bucindolol (Primary) ; Metoprolol succinate
  • Indications Atrial fibrillation; Atrial flutter; Heart failure
  • Focus Therapeutic Use
  • Acronyms GENETIC-AF
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 10 Sep 2017 This trial is dicontinued in Bulgaria.
    • 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Aug 2017 According to an ARCA Biopharma media release, enrollment in the phase IIb portion of the trial has been completed. Two-hundred sixty-seven patients were randomized into the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top